The head of the top federal medical research agency said in a new interview that marijuana’s status as a Schedule I drug inhibits studies into the plant and prevents scientists from researching the effects of cannabis that consumers are obtaining from state-legal dispensaries in a growing number of states.
Francis Collins, director of the National Institutes of Health (NIH), discussed the limitations imposed by the federal drug scheduling system during an appearance on C-SPAN’s Newsmakers that aired last week, saying that while he shares concerns about the potential health implications of smoking marijuana, research into the risks and benefits of cannabis is being impeded by current policy.
“Frankly, we know far too little about the benefits and risks of smoked marijuana,” Collins said. “There have been very few studies that have actually rigorously tested that.”
The director said scientists are in a “funny place” in the U.S. when it comes to cannabis,…
This is just an excerpt, please Click here to read content on original website.